Skip to main content

Meniere's Disease

6
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Alvogen
AlvogenNJ - Morristown
2 programs
2
MeniacePhase 41 trial
meclizine and isosorbidePhase 4
Active Trials
NCT02718846Completed220Est. May 2015
Pfizer
PfizerNEW YORK, NY
1 program
1
SildenafilPhase 41 trial
Active Trials
NCT00145483Completed163Est. Nov 2006
Sound Pharmaceuticals
3 programs
1
1
1
EbselenPhase 31 trial
200mg SPI-1005 BIDPhase 21 trial
SPI-1005Phase 1/21 trial
Active Trials
NCT02603081Completed40Est. Aug 2017
NCT03325790Completed149Est. Apr 2019
NCT06859788Recruiting200Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AlvogenMeniace
PfizerSildenafil
Sound PharmaceuticalsEbselen
Sound Pharmaceuticals200mg SPI-1005 BID
Sound PharmaceuticalsSPI-1005

Clinical Trials (5)

Total enrollment: 772 patients across 5 trials

NCT02718846AlvogenMeniace

Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets

Start: Feb 2013Est. completion: May 2015220 patients
Phase 4Completed
NCT00145483PfizerSildenafil

Sildenafil For Meniere's Disease

Start: Jun 2002Est. completion: Nov 2006163 patients
Phase 4Completed
NCT06859788Sound PharmaceuticalsEbselen

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Start: Oct 2025Est. completion: Dec 2026200 patients
Phase 3Recruiting
NCT03325790Sound Pharmaceuticals200mg SPI-1005 BID

SPI-1005 for the Treatment of Patients With Meniere's Disease

Start: Sep 2017Est. completion: Apr 2019149 patients
Phase 2Completed
NCT02603081Sound PharmaceuticalsSPI-1005

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Start: Dec 2015Est. completion: Aug 201740 patients
Phase 1/2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 772 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.